Currently available therapies are too burdensome for those with food allergies. Intrommune Therapeutics is developing an easy-to-use toothpaste-based platform that makes allergen introduction as simple as brushing your teeth.
About Us
With over 33 million Americans suffering from food allergies, Intrommune is focused on developing a safe, disease-modifying treatment with long-term efficacy through our oral mucosal immunotherapy (OMIT) platform that can help provide a much-needed solution.
Our novel drug delivery platform provides an elegant solution for food allergies by embedding therapeutic agents in a fully functional toothpaste that can be conveniently administered as daily treatment at the same time patients brush their teeth.